Health economic models are crucial for setting healthcare priorities and assessing the financial value of interventions, especially given the limitations of randomised clinical trials (RCTs). Cardiovascular disease (CVD) is the leading global cause of death, but prevention efforts often start too late. Long-term prevention studies are expensive and challenging, making epidemiological modelling, such as Mendelian Randomisation, essential. The health economic model for the primary prevention of cardiovascular disease (HEM-PPCVD) model will appropriately capture all costs and value health outcomes of existing and new health interventions and this approach will identify at-risk individuals early when we take into consideration the cumulative impact of modifiable risk factors, ultimately saving lives and improving access to preventive measures.